Indeed, our PD-1–laIL-2 specifically delivers IL-2 to exhausted tumor-specific T cells marked by high PD-1 and TIM3 expression and expands them with enhanced antitumor polyfunctionality, as indicated by high expression of IFN-γ and CD107a. The gene discussed is HAVCR2; the disease is neoplasm.